Prostate cancer, version 1.2014.

Authors:
  • JMJames L. Mohler
    James L. Mohler
  • PKPhilip W. Kantoff
    Philip W. Kantoff
  • AAAndrew J. Armstrong
    Andrew J. Armstrong
  • RBRobert R. Bahnson
    Robert R. Bahnson
  • MCMichael Cohen
    Michael Cohen
  • ADAnthony Victor D’amico
    Anthony Victor D’amico
  • JEJames A. Eastham
    James A. Eastham
  • CECharles A. Enke
    Charles A. Enke
  • TFThomas A. Farrington
    Thomas A. Farrington
  • CHCelestia S. Higano
    Celestia S. Higano
  • EHEric Mark Horwitz
    Eric Mark Horwitz
  • MKMark H. Kawachi
    Mark H. Kawachi

Abstract
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.